Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Myeloid leukemia: ọgwụgwọ ọhụụ ọhụrụ

Ascentage Pharma, ụlọ ọrụ biopharmaceutical zuru ụwa ọnụ na-arụ ọrụ na-emepụta usoro ọgwụgwọ ọhụrụ maka ọrịa cancer, ịba ọcha n'anya B (CHB), na ọrịa ndị metụtara afọ, na Innovent Biologics, Inc. ("Innovent"), ụlọ ọrụ biopharmaceutical nke ụwa nke na-emepụta, na-emepụta ihe. ma na-ere ahịa ọgwụ dị elu maka ọgwụgwọ oncology, metabolic, autoimmune na ọrịa ndị ọzọ bụ isi, na-ekwupụta ọnụ na onye na-akwado ọgwụ ọhụrụ olverembatinib nke Guangzhou HealthQuest Pharma Co., Ltd., Inc., onye enyemaka nke Ascentage Pharma, nwere kpamkpam. Ụlọ Ọrụ Na-ahụ Maka Ọgwụ Na-ahụ Maka Ọgwụ nke Mba China (NMPA) kwadoro maka ọgwụgwọ nke ndị okenye nwere tyrosine kinase inhibitor (TKI) na-eguzogide ọgwụ na-adịghị ala ala myeloid leukemia (CML-CP) ma ọ bụ accelerated-phase CML (CML-AP) na-eburu T315I. ngbanwe dị ka akwadoro site na nnwale diagnostic akwadoro (ihe ngosi nke akwadobeghị na US).

Print Friendly, PDF & Email

Emepụtara site na Ascentage Pharma site na nkwado sitere na mmemme nchọpụta na nrụpụta ọgwụ ọhụrụ nke National Major, olverembatinib bụ ọgwụ nwere ike kacha mma na klaasị nke Innovent na Ascentage Pharma ga-ejikọ ọnụ na ahịa China na ahịa, maka abamuru nke ọtụtụ ndị ọrịa na ha. ezinụlọ. Dị ka ọgbọ mbụ nke China nke atọ BCL-ABL TKI mepụtara maka ọgwụgwọ nke CML na-eguzogide TKI, nkwenye a na-ejupụta oghere ọgwụgwọ dị mkpa na T315I-mutant CML, ma gosipụta isi ihe dị ịrịba ama na-egosi na Ascentage Pharma abanyela n'ọgbọ azụmahịa nke ọma.

Nkwenye a maka olverembatinib gbadoro ụkwụ na nsonaazụ sitere na ọmụmụ ihe abụọ dị mkpa - ihe ọmụmụ HQP1351CC201 na ọmụmụ HQP1351CC202. Nsonaazụ ndị a gosiri na olverembatinib dị irè ma na-anabata ya nke ọma na ndị ọrịa nwere CML-CP na CML-AP, a na-atụkwa anya na ihe gbasara omume na omimi nke nzaghachi ọgwụgwọ ga-abawanye na oge ọgwụgwọ ogologo oge.

CML bụ ajọ ọrịa hematologic nke mkpụrụ ndụ ọbara ọcha. Iwebata BCR-ABL TKI emeela ka nlekọta ahụike nke CML dịkwuo mma. Agbanyeghị, nguzogide enwetara na TKI ka bụ nnukwu ihe ịma aka na ọgwụgwọ CML. Mmụba nke BCR-ABL tyrosine kinase na-anọchite anya usoro bụ isi nke enwetara nguzogide ọgwụ; T315I, nke bụ ngbanwe kachasị na-eguzogide ọgwụ, na-eme n'ihe dịka 25% nke ndị ọrịa nwere CML na-eguzogide ọgwụ. Ndị ọrịa nwere T315I-mutant CML na-eguzogide ma ndị na-egbochi BCR-ABL nke mbụ na ọgbọ nke abụọ, ya mere ọ na-eweta mkpa ahụike na-enweghị ngwa ngwa maka ọgwụgwọ dị irè.

Print Friendly, PDF & Email

Banyere chepụtara

Linda Hohnholz, onye editọ eTN

Linda Hohnholz na-ede ma na-edezi isiokwu kemgbe ọ malitere ọrụ ya. O tinyela obi uto nke a dika ebe Hawaii Pacific University, Chaminade University, Hawaii Discovery Center, ma ugbu a TravelNewsGroup.

Ahapụ a Comment